MedTrace Logo

The Role of Fibroblast Activation in Uterine Fibroid

NCT03444987 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 35

Last updated 2021-02-09

No results posted yet for this study

Summary

Uterine fibroids (UFs), also called uterine leiomyomas or myomas, are steroid hormone-responsive, benign tumors of the smooth muscle compartment (myometrium) of the uterus. They are the most common neoplasm affecting women in their reproductive age. It is estimated that up to 77% of women develop UF in their life. UFs are one of the leading causes of hospitalisations for gynaecological disorders and are the most frequent reason for hysterectomy. According to relevant literature, 40%-60% of all the hysterectomies performed are due to the presence of UFs.

Conditions

  • Uterine Fibroid

Interventions

GENETIC

Measurement of protein expression in tissues.

The followings markers will be estimated in tissue 1. FAP, a marker of fibroblast activation, using quantitative real time polymerase chain reaction qRTPCR (mRNA level) and ELISA (protein level). 2. Markers of autophagy including LC3 and p62 using qRTPCR (mRNA level) and by immunohistochemical analysis. 3. Phosphorylated protein kinase B (pAKT) level by ELISA (protein level). 4. Markers of oxidative stress (Malondialdehyde as lipid peroxide) by a colorimetric method. 5. Reduced glutathione, an antioxidant marker by a colorimetric method

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Nashwa AbdelGhfar El Maghraby, MD student) · Assiut University

  • Eman Magdy Mohamed, Lecturer · Assiut University

  • Ahmed Mohamed Abass, Lecturer · Assiut University

Eligibility

Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-03-01
Primary Completion
2019-11-01
Completion
2020-03-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03444987 on ClinicalTrials.gov